Prescrire welcomes the stronger focus on the prevention of medication errors, the introduction of a preliminary assessment by marketing authorisation holders (MAH) and the opposition to "umbrella brands". But Prescrire also expressed concerns, especially as regards the correct use of International Non-proprietary Names (INN) by the European Medicines Agency (EMA) and MAH; and threats to EMA's independence, if the agency becomes involved in negotiations with companies for possible re-use or "conditional acceptability" of names. Read on...